Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 139,591 shares of the company’s stock, valued at approximately $498,000. Raymond James Financial Inc. owned 0.15% of Aquestive Therapeutics as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AQST. Harvey Capital Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after buying an additional 249,790 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after buying an additional 82,958 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Aquestive Therapeutics by 233.6% in the 4th quarter. Renaissance Technologies LLC now owns 95,400 shares of the company’s stock valued at $340,000 after purchasing an additional 66,800 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Aquestive Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after acquiring an additional 7,347 shares during the period. Finally, New York State Common Retirement Fund boosted its position in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

AQST has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Lake Street Capital dropped their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $10.67.

Aquestive Therapeutics Trading Up 0.9 %

Shares of NASDAQ:AQST opened at $2.76 on Friday. Aquestive Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $5.80. The firm’s 50 day moving average is $2.78 and its two-hundred day moving average is $3.49. The firm has a market capitalization of $273.63 million, a P/E ratio of -6.12 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. Analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.